Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

• Status: Completed
• Trial end date: 2017-12-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LG Life Sciences

Criteria

Inclusion Criteria:

• Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks

• Subjects who meets the indication of EutropinPen inj.

Exclusion Criteria:

• Subjects who has diseases below on screening visit

• Diabetes

• Malignant tumor

• Epiphyseal closure

• Chronic kidney disease (recieved kidney transplantation)

• Acute respitory failure